tiprankstipranks
BioNTech raises FY22 COVID-19 vaccine revenue view to EUR 16B-EUR 17B
The Fly

BioNTech raises FY22 COVID-19 vaccine revenue view to EUR 16B-EUR 17B

Prior view was EUR 13B-EUR 17B. The updated guidance reflects the shipment of the Omicron-adapted bivalent vaccine boosters, which started early in September and is expected to continue throughout the fourth quarter of 2022 as well as higher prices and a positive foreign currency effect. This revenue estimate reflects expected revenues related to BioNTech’s (BNTX) share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territories, from direct COVID-19 vaccine sales to customers in BioNTech’s territory and expected revenues generated from products manufactured by BioNTech and sold to collaboration partners. BioNTech’s COVID-19 vaccine gross profit share from Pfizer (PFE) is impacted by inventory write-offs. Pfizer inventory write-offs for COVID-19 products reduce BioNTech’s gross profit share and therefore, reduce BioNTech’s vaccine revenues.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on BNTX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles